To be successful in Oncology, innovators know that they must adapt to an ever-changing market. The historical "special status" in which Oncology products even with little-demonstrated benefit were automatically reimbursed, has been replaced by new evaluation criteria and increasing scrutiny. Nonetheless, it is still common for small and mid-spaced companies with products in early development to postpone pricing and reimbursement and medical affairs issues until preparing for commercialization or abdicating responsibility to a commercialization partner not recognizing that strengthening their product value proposition earlier in development can increase bargaining power and associated royalty payments or a product's selling price which translates directly into increased profitability. It is no longer sufficient to develop an efficacious and safe product. Today's market is demanding products that demonstrate comparative clinical and economic effectiveness or risk being non-reimbursable and therefore non-profitable. Value Genome believes that innovative companies need to take a different approach by tailoring their clinical program to reveal the clinical and economic value of their assets as defined by relevant stakeholders including patients, professional and patient organization, Oncologists and treatment centers, government and commercial payers and health technology assessment organizations. Value Genome is a collaboration between former pharmaceutical and biotechnology executives who share a common passion for assisting innovators to actualize the clinical and economic value of their assets. We combine our scientific, clinical, economic and commercialization expertise with extensive payer and KOL research and relations experience. We enjoy partnering with innovators to ensure their many years of effort are translated into the highest possible financial return whether their goal is licensing, acquisition, or bringing a life changing product to market.